Mabwell Therapeutics, Inc.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
TMPRSS6 (matriptase-2)Monoclonal antibody
Sickle Cell DiseasePolycythemia Vera

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
DISC-3405Phase 2Polycythemia Vera (PV)
Est. primary completion 2027-07 · NCT06985147 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.